EVOKE PHARMA INC (EVOK) Stock Analyst Earnings Estimates
NASDAQ:EVOK - Nasdaq - US30049G3020 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.62M 8,000.00% | 2.51M 54.94% | 5.181M 106.40% | 10.224M 97.35% | 20.399M 99.52% | 32.67M 60.15% | |
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -8.15M 37.55% | -7.79M 4.42% | -7.431M 4.61% | -5.155M 30.63% | 2.113M 140.99% | 12.186M 476.72% | |
| Operating Margin | -503.09% | -310.36% | -143.44% | -50.42% | 10.36% | 37.30% | |
| EPS YoY % growth | -38.88 48.08% | -32.16 17.28% | -27.96 13.06% | -4.06 85.48% | 0.49 112.06% | 2.64 439.58% |
All data in USD
| Q4 / 24 | |
|---|---|
| EPS Q2Q % growth | -0.64 90.92% |
| Revenue Q2Q % growth | 3.146M 87.71% |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -1.064M 43.65% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.94 84.64% | -0.39 | -0.55 | -142.52% |
| Q2 2024 Q2Q % growth | -0.93 86.16% | -0.73 | -0.20 | -26.63% |
| Q1 2024 Q2Q % growth | -2.04 74.63% | -2.57 | 0.53 | 20.63% |
| Q4 2023 Q2Q % growth | -7.08 -11.32% | -6.12 | -0.96 | -15.69% |
| Q3 2023 Q2Q % growth | -6.12 15.00% | -7.59 | 1.47 | 19.35% |
| Q2 2023 Q2Q % growth | -6.72 21.13% | -8.94 | 2.22 | 24.79% |
| Q1 2023 Q2Q % growth | -8.04 20.24% | -7.10 | -0.94 | -13.25% |
| Q4 2022 Q2Q % growth | -6.36 26.39% | -6.49 | 0.13 | 1.96% |
| Q3 2022 Q2Q % growth | -7.20 16.67% | -8.08 | 0.88 | 10.87% |
| Q2 2022 Q2Q % growth | -8.52 15.48% | -7.34 | -1.18 | -16.01% |
| Q1 2022 Q2Q % growth | -10.08 12.50% | -5.88 | -4.20 | -71.57% |
| Q4 2021 Q2Q % growth | -8.64 33.33% | -11.75 | 3.11 | 26.47% |
| Q3 2021 Q2Q % growth | -8.64 25.00% | -10.28 | 1.64 | 15.97% |
| Q2 2021 Q2Q % growth | -10.08 75.00% | -11.75 | 1.67 | 14.22% |
| Q1 2021 Q2Q % growth | -11.52 -14.29% | -9.55 | -1.97 | -20.66% |
| Q4 2020 Q2Q % growth | -12.96 -50.00% | -19.83 | 6.87 | 34.64% |
| Q3 2020 Q2Q % growth | -11.52 -14.29% | -12.48 | 0.96 | 7.73% |
| Q2 2020 Q2Q % growth | -40.32 -211.11% | -11.75 | -28.57 | -243.14% |
| Q1 2020 Q2Q % growth | -10.08 36.36% | -7.34 | -2.74 | -37.25% |
| Q4 2019 Q2Q % growth | -8.64 | -8.81 | 0.17 | 1.96% |
| Q3 2019 Q2Q % growth | -10.08 | -13.22 | 3.14 | 23.75% |
| Q2 2019 Q2Q % growth | -12.96 | -17.63 | 4.67 | 26.47% |
| Q1 2019 Q2Q % growth | -15.84 | -10.28 | -5.56 | -54.06% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 2.654M 69.82% | 3.425M | -771K | -22.51% |
| Q2 2024 Q2Q % growth | 2.551M 125.55% | 3.04M | -489K | -16.09% |
| Q1 2024 Q2Q % growth | 1.735M 114.26% | 2.181M | -445.51K | -20.43% |
| Q4 2023 Q2Q % growth | 1.676M 109.50% | 1.665M | 10.99K | 0.66% |
| Q3 2023 Q2Q % growth | 1.563M 88.30% | 1.288M | 274.86K | 21.34% |
| Q2 2023 Q2Q % growth | 1.131M 145.87% | 1.118M | 13K | 1.16% |
| Q1 2023 Q2Q % growth | 810K 92.86% | 1.023M | -213K | -20.82% |
| Q4 2022 Q2Q % growth | 800K 122.22% | 906.78K | -106.78K | -11.78% |
| Q3 2022 Q2Q % growth | 830K -10.75% | 583.44K | 246.56K | 42.26% |
| Q2 2022 Q2Q % growth | 460K 91.67% | 591.6K | -131.6K | -22.24% |
| Q1 2022 Q2Q % growth | 420K 366.67% | 545.7K | -125.7K | -23.03% |
| Q4 2021 Q2Q % growth | 360K 1,700.00% | 517.14K | -157.14K | -30.39% |
| Q3 2021 Q2Q % growth | 930K | 389.64K | 540.36K | 138.68% |
| Q2 2021 Q2Q % growth | 240K | 154.02K | 85.98K | 55.82% |
| Q1 2021 Q2Q % growth | 90K | 849.66K | -759.66K | -89.41% |
| Q4 2020 Q2Q % growth | 20K | 861.9K | -841.9K | -97.68% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | -64.46% |
| Revenue | 0% | 0% | 0% | -11.94% |